Although there are big prognosis differences across these genetic groups, the current approach for young and fit patients is a standard induction cytotoxic therapy (“3+7”) (14, 17) with the addition of targeted therapies, mainly FLT3 inhibitors, to a specific group of AML patients (14). The gene discussed is FLT3; the disease is acute myeloid leukemia.